Rapid adoption NG2 is a fully autonomous transcranial Doppler system with real-time, automated brain imaging that is fully reimbursable under existing CPT codes, signaling a clear path for hospital, ASC, stroke center, and rural clinic deployments.

Expands stroke care NeuraSignal claims to triple PFO detection versus standard echo and identify nearly three times as many treatable shunts, positioning NG2 as a compelling platform for hospitals seeking to reduce cryptogenic stroke risk and drive better patient outcomes.

Reimbursement readiness With existing CPT coverage (93886, 93892, 93893), the sales angle can emphasize rapid payer acceptance and quicker clinical implementation, reducing reimbursement friction for new customers.

Diverse market Target segments include large academic centers, community hospitals, ambulatory surgery centers, and rural clinics, all of which benefit from AI-enabled, hands-free TCD exams and improved neurovascular imaging without specialized technicians.

Strong backing Funding of substantial scale combined with a growing revenue trajectory and a recent product launch in NG2 suggests a scalable growth story for enterprise collaborations, strategic partnerships, and multi-site deployments.